Login to Your Account

Other News To Note

Tuesday, July 31, 2012
• Arena Pharmaceuticals Inc., of San Diego, transferred the Belviq (lorcaserin hydrochloride) new drug application to partner Eisai Inc., of Woodcliff Lake, N.J., which establishes Eisai as the marketing authorization holder responsible for regulatory activities in the U.S. related to commercialization of the obesity drug, including pharmacovigilance requirements. Belviq gained FDA approval last month.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription